Principles and Practice of Emergency Research Response

Name: Principles and Practice of Emergency Research Response
ISBN: 9783031484070

Language: English

Published by Springer, Berlin|Springer International Publishing|National Institute of Allergy and Infectious Diseases|Springer, 2024

303148407X / 9783031484070

Hardcover
New

See all details

Seller: moluna, Greven, Germanymoluna

5-star seller

AbeBooks seller since July 9, 2020

View this seller's items

Hardcover

Condition: New

£ 65.53

£ 41.39 shipping

Ships from Germany to U.S.A.

Quantity: Over 20 available

Add to basket

Free 30-day returns

Save for laterCreate a Want for similar items

Item description from seller

Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Unlocking the Future of Infectious Disease Research ResponseIn a world where emerging infectious diseases constantly threaten humanity, advances in science and technology promise defense against future pathogens before they cause pandemics. The field.

Seller Inventory # 1171875023

Contact seller about this item

Report this item

Title: Principles and Practice of Emergency Research Response
Publisher: Springer, Berlin|Springer International Publishing|National Institute of Allergy and Infectious Diseases|Springer
Publication year: 2024
Condition: New
Binding: Hardcover
Language: English
ISBN 10: 303148407X
ISBN 13: 9783031484070

Unlocking the Future of Infectious Disease Research Response

In a world where emerging infectious diseases constantly threaten humanity, advances in science and technology promise defense against future pathogens before they cause pandemics. The field of emergency research response and preparedness remains in its infancy, however. Not until the 2014 West African Ebola outbreak was accelerated research broadly recognized as a crucial component of emergency response. Many outbreaks and one global pandemic later, it is clear the world must be prepared to launch accelerated research responses to prevent or mitigate infectious disease outbreaks, epidemics, and pandemics. Yet this nascent field is rife with critical scientific, ethical, and policy questions.

How can local, national, and global systems collaborate across disciplines and political boundaries to protect health security? How can we conduct rigorous research in fragile or failed nation-states? What is needed for equitable distribution of vaccines and therapeutic medicines in short supply? How can we accelerate trials of vaccines and therapeutics during an emergency without compromising scientific rigor or ethical standards? How do we integrate communities and stakeholders into research preparedness and response?

The editors bring decades of experience to their collaboration with renowned research scientists and health policy experts. Together they have crafted a compendium that proposes normative standards and offers practical guidance for preparedness and rapid research response. This pioneering, open access textbook presents principles and practices forged from experience in health emergencies – insights that illuminate a path forward for research response and preparedness. The goal is to stop outbreaks from becoming avoidable pandemics, and to mitigate illness, death, and social disruption if they cannot be stopped.

Principles and Practice of Emergency Research Response merges historical understanding with insights into possible futures. It will serve as an indispensable compass for curtailing infectious disease threats through research, global health policy changes, and research capacity improvements where they are most needed. The editors hope that this book will be an ongoing reference for governments, health organizations, development agencies, researchers, policy experts, ethicists, and social scientists. To facilitate focused and enhanced learning, it incorporates pedagogical tools such as abstracts, learning objectives, discussion questions, real-life examples, and learning tracks.

Robust global health security requires effective preparation for and response to emerging and re-emerging pathogens. This volume should help guide us towards a more resilient future.

"Synopsis" may belong to another edition of this title.

About the Author

Dr. Elizabeth S. Higgs, MD, MIA, DTMH, is a global health science advisor, clinical scientist, and pandemic preparedness research response policy expert working in the Division of Clinical Research at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Throughout her career, Dr. Higgs has contributed to critical health emergencies, including H1N1, Ebola outbreaks in West Africa and the DRC, the 2018 Nipah outbreak in Kerala, India, mpox, and SARS-CoV-2, demonstrating that regulatory-level clinical trials during health emergencies are possible and contribute to medical countermeasures that accelerate the end of outbreaks.

Known for global health diplomacy while fostering interagency and multilateral collaborations, she actively engages in strategic global health security initiatives and policy groups, making impactful contributions to key policy documents such as the World Bank's Money and Microbes, the G7 Clinical Trials Charter, and the U.S. National Biosecurity Strategy and Global Health Security Strategy.

Her passions include nurturing sustainable clinical research capacity in low- and middle-income countries and promoting cooperative global clinical trial networks. With a foundation in internal medicine and infectious diseases, Dr. Higgs holds a doctorate in medicine, a master’s degree in international affairs, an interdisciplinary bachelor's degree in bioethics, and a Diploma in Tropical Medicine and Hygiene. Through her commitment to response research, she is dedicated to safeguarding and enhancing the well-being of people worldwide in the face of health emergencies caused by emerging infectious disease.

Robert A. Sorenson has worked with the NIAID Division of Clinical Research on infectious disease emergency response policy, especially urgent clinical research response to emerging pathogens, since 2016, after having worked on global health policy issues at the U.S. Department of State since 2009.

Mr. Sorenson was a Foreign and Civil Service Officer at State for 33 years. After 2001, when family circumstances curtailed his overseas career, he primarily served in the Bureau of Oceans, Environment, and Science, including terms as Deputy Director of the Offices of International Health and Biodefense, Environmental Policy, and Ecology and Terrestrial Conservation. His overseas experience, starting in 1986, included political, consular, environmental, and deputy chief of mission positions in Manila, Moscow, Osaka, Skopje, Tashkent, and Tirana, as well as several temporary duty assignments in crisis spots. He retired from State on New Year’s Eve, 2017 and has since been a contractor with NIAID.

As managing editor of PPERR, Mr. Sorenson revived and updated his professional editorial experience, which dated to 1981-1986. He wasa National Fellow at the Hoover Institution in 1999-2000 and has an MA in Russian literature from Cornell University and a BA from St. Olaf College

Nicole Lurie, M.D., M.S.P.H., is Executive Director for Preparedness and Response at the Coalition for Epidemic Preparedness Innovations (CEPI) and Director of CEPI-US. She is also a Senior Lecturer at Harvard Medical School and Professor of Medicine at George Washington University School of Medicine.

She served an eight-year term as Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services from 2009 to 2017. In that role she led the HHS response to numerous public health emergencies, ranging from infectious disease to natural and man-made disasters, and is responsible for many innovations in emergency preparedness and response.

Prior to federal service, she was the Paul O'Neill Professorof Policy Analysis at RAND, and a Professor of Medicine and Public Health at the University of Minnesota. Her research has spanned access to and quality of care, health system redesign, health equity, mental health, public health, and preparedness. She is the recipient of numerous awards and is a member of the National Academy of Medicine. She continues to practice medicine in a community clinic in Washington DC.

Peter Smith is Professor of Tropical Epidemiology at the London School of Hygiene &Tropical Medicine (LSHTM).

He graduated in mathematics and statistics from City University, London and in 1965 joined the Medical Research Council's Statistical Research Unit in London. Since then, he has worked on various aspects of epidemiological and statistical research based in Edinburgh, Kampala, Oxford, Boston and Geneva. He joined LSHTM in 1979 to head the MRC International Statistics & Epidemiology Group. Research interestsinclude large-scale intervention studies against tropical diseases, recently focussing on vaccines.

From 1999 to 2004 Dr. Smith chaired the UK Government Spongiform Encephalopathy Advisory Committee. He has chaired the WHO Global Advisory Committee on Vaccine Safety and the WHO Technical Expert Group on the RTS,S/AS01 malaria vaccine. He served as the Deputy Chair of the Nuffield Council on Bioethics and from 2004 to 2014 was a Governor of the Wellcome Trust. He has served on the Scientific Advisory Committees of the Coalition for Epidemic Preparedness Innovations (CEPI) and the European and Developing Countries Clinical Trials Partnership (EDCTP). He chairs the WHO SAGE Working Group on malaria vaccines and serves on the WHO SAGE Working Group on SARS-CoV-2 vaccines.

Laura Ann McNay, MS, is the Deputy Director for Operations and Management in the Division of Clinical Research, NIAID. She started her career at NIAID in 1991 and has served in many roles at NIAID over the past 32 years. During Ms. McNay's tenure with DCR, she has been responsible for the management and oversight of numerous small and large, multinational clinical trials.

In addition to her role as DCR Deputy Director for Operations and Management, she serves as the DCR Project Lead for the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL). PREVAIL is a clinical research partnership between the U.S. Department of Health and Human Services (DHHS) and the Liberian Ministry of Health.

Ms. McNay attended the University of Maryland Baltimore County where she received her bachelor’s degree in economics in 1987. In 2002, she received her Master of Science in Management and Healthcare Administration.

Mosoka P. Fallah, PhD, MPH, MA is Program Manager of the Saving Lives and LivelihoodsInitiative, Africa Centres for Disease Control and Prevention. The Initiative supports the acquisition and distribution of 65 million COVID-19 vaccine doses and has a mandate to focus on turning vaccine deliveries into vaccinations. Dr. Fallah completed his PhD in Immunology at the University of Kentucky and his MPH in Global Health/Infectious Disease Epidemiology at the Harvard T. H. Chan School of Public Health. For his work building community-level trust in the Ebola response, Dr. Fallah was named one of the Time Magazine Persons of the Year in 2014.

Dr. Fallah was also the co-founder and Director General of the National Public Health Institute of Liberia (NPHIL), which was founded in response to the devastation of the 2014-2016 Ebola outbreak in Liberia. He has also held positions as a health security technical consultant on pandemic diagnostics with the World Bank, visiting lecturer at Harvard Medical School, and senior consulting scientist atMedical Science & Computing, LLC. He continues to serve as President and CEO of Refuge Place International (RPI), a non-governmental organization dedicated to creating a replicable health care model for economically poor and disenfranchised people residing in the urban slums and poor rural communities of Liberia.

"About the title" may belong to another edition of this title.

moluna

Greven, Germany

5-star seller

AbeBooks seller since July 9, 2020

Shipping rates from Germany to U.S.A.

Item	16 to 45 business days	16 to 45 business days
First item	£ 41.39	£ 41.39

Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.

Payment methods

Bank Wire Transfer
Check
Paypal

Store description

Online Handel nur mit Neubüchern

Seller's business information

Moluna GmbH

Engberdingdamm 27
Greven, Germany 48268

Contact sellerView this seller's itemsView seller's storefront

Terms of sale

About Us

Legal website operator identification:

Moluna GmbH
Represented by the general manager Helge Blischke
Engberdingdamm 27
48268 Greven
Germany
Telephone: 02571/5698933
Telefax: 02571/5698930
E-Mail: abe@moluna.de
VAT No.: DE296281834
listed in the commercial register of the local court Steinfurt
Commercial register number - Part B of the commercial register - 10553

We are a member of the initiative „FairCommerce“ since 24.07.2015.
For more information, see: www.haendlerbund.de/faircommerce.

Right of withdrawal

If you are a consumer you can withdraw from the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.

Information regarding the right of withdrawal

Statutory right to withdraw

You have the right to withdraw from this contract within 14 days without giving any reason.

The withdrawal period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the last good or the last lot or piece.

To exercise the right of withdrawal, electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". We will communicate to you an acknowledgement of receipt of such a withdrawal on a durable medium (e.g. by e-mail) without delay.

To meet the withdrawal deadline, it is sufficient for you to send your communication concerning your exercise of the right of withdrawal before the withdrawal period has expired.

Effects of withdrawal

If you withdraw from this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).

We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.

We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to withdraw from this contract.

We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.

We may withhold reimbursement until we have received the goods back, or you have supplied evidence of having sent back the goods, whichever is the earliest.

You shall send back the goods or hand them over to moluna, Greven, Germany, without undue delay and in any event not later than 14 days from the day on which you communicate your withdrawal from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.

Exceptions to the right of withdrawal

The right of withdrawal does not apply to:

The delivery of newspapers, journals or magazines with the exception of subscription contracts; and
The supply of digital content which is not supplied on a tangible medium (e.g. on a CD or DVD) if you accepted when you placed your order that we could start to deliver it, and that you could not withdraw once delivery had started.